The FDA clears Olympus for its high definition 3D video imaging system for laparoscopic surgery.
Olympus (PINK:OCPNY) won 510(k) clearance for its Articulating HD 3D laparoscopic surgical video system, which provides an additional 3D option to the company's Evis Exera III imaging system.
Sony Corp. plans to acquire an 11% stake in beleaguered Olympus Corp. for $642 million.
Sony Corp. (TYO:6758) plans to become the largest shareholder in Olympus (TYO:7733) with a $642 million investment that will give it an 11% stake in Olympus.
Japan's Terumo Corp. proposes a merger with Olympus Corp., aiming for a buyout to block rival companies' advances.
Asian medical device giant Terumo Corp. (TYO:4543) confirmed rumors of a proposed buyout of Olympus (PINK:OCPNY) in the aftermath of a $1.7 billion accounting scandal.
Stryker's plans to cut more than 100 jobs by closing 2 New York manufacturing facilities will begin in September and continue on a rolling basis until the end of the year, just ahead of implementation of the 2.3% medical device tax.
Stryker (NYSE:SYK) is making good on plans to cut more than 100 positions by closing 2 New York manufacturing plants, moves that the company previously attributed to attempts to cut costs ahead of the coming 2.3% medical device tax.
Panasonic president Fumio Ohtsubo tells reporters that rumors of a $630 million investment into scandal-stricken Olympus are untrue.
A Federal Circuit decision reinstating HemCon Medical's $34M patent infringement loss pushes the wound care company into Chapter 11 bankruptcy protection; also, proxy advisor tells Olympus backers to reject board nominees; Israeli device makers on the ropes; PositiveID is taking orders; Orgenesis inks research deal; pricing pressure unlikely to abate for device makers; Premier inks laser deals; plus, a Funding Roundup and analysts' ups and downs.
HemCon Medical Technologies said it's filing for Chapter 11 bankruptcy protection for its U.S. operation after losing a $34.2 million court decision last month, saying it plans to appeal the ruling.
In March a sharply split U.S. Court of Appeals for the Federal Circuit reversed course and reinstated a win for Marine Polymer Technologies in its wound dressing patent spat with HemCon.
Coming off of an accounting scandal that cut the company's assets by nearly 30%, Olympus may look to raise investor confidence through strategic alliances.
MASSDEVICE ON CALL — A post-scandal Olympus (PINK:OCPNY) is considering strategic alliances to boost investor confidence, having received at least 3 offers from potential partners.